PMID- 24292945
OWN - NLM
STAT- MEDLINE
DCOM- 20140725
LR  - 20240323
IS  - 0219-1032 (Electronic)
IS  - 1016-8478 (Print)
IS  - 1016-8478 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Dec
TI  - Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of 
      ischemic brain damage in rats.
PG  - 534-41
LID - 10.1007/s10059-013-0235-2 [doi]
AB  - Ziprasidone is a benzisothiazolyl piperazine derivative that was developed from 
      the chemically related antipsychotic drug tiospirone, and it improves 
      neurological functions of the ischemic brain and is effective in treatment of 
      schizophrenia. Mesenchymal stem cells (MSCs) are considered as a leading 
      candidate for neurological regenerative therapy because of their neural 
      differentiation properties in damaged brain. We investigated whether the 
      transplantation of neural progenitor cells (NPCs) derived from adipose 
      mesenchymal stem cells combined with ziprasidone enhances neuroprotective effects 
      in an animal model of focal cerebral ischemia. In combination therapy groups, 
      significant reduction of infarct volume and improvement of neurological functions 
      were observed at 3 days after middle cerebral artery occlusion (MCAO) compared 
      with monotherapy. Co-administration of ziprasidone and NPCs enhanced the 
      anti-apoptotic effect and reduced the number of terminal deoxynucleotidyl 
      transferase dUTP nick end labeling (TUNEL)-positive apoptotic cells compared with 
      the NPCs alone group at 7 days after MCAO. Ziprasidone or the combination of 
      ziprasidone and NPCs induced the expression of endogenous neurotrophic factor 
      gene brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and 
      glial cell-derived neurotrophic factor (GDNF). The immunohistochemical 
      investigation revealed that the ziprasidone and NPCs attenuated the increased 
      intensity of microglial marker (Iba-1) in the infarcted cortical area. Moreover, 
      the number of transplanted NPCs on day 7 with combination therapy was 
      significantly higher than with NPCs alone. These effects might be responsible for 
      improved functional behavior and increased survival of NPCs. Our finding 
      indicates that combination therapy of ziprasidone and NPCs enhances 
      neuroprotection against ischemic brain injury.
FAU - Kaengkan, Phatcharida
AU  - Kaengkan P
AD  - Department of Biological Sciences, Institute of Basic Science, Inje University, 
      Gimhae, 621-749, Korea.
FAU - Baek, Seung Eun
AU  - Baek SE
FAU - Kim, Ji Yeong
AU  - Kim JY
FAU - Kam, Kyung-Yoon
AU  - Kam KY
FAU - Do, Byung-Rok
AU  - Do BR
FAU - Lee, Eun Shin
AU  - Lee ES
FAU - Kang, Sung Goo
AU  - Kang SG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131128
PL  - United States
TA  - Mol Cells
JT  - Molecules and cells
JID - 9610936
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Piperazines)
RN  - 0 (Thiazoles)
RN  - 6UKA5VEJ6X (ziprasidone)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Animals
MH  - Brain Ischemia/physiopathology/*therapy
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cell Survival/drug effects
MH  - Combined Modality Therapy
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Glial Cell Line-Derived Neurotrophic Factor/metabolism
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Microglia/drug effects
MH  - Nerve Growth Factor/metabolism
MH  - Neural Stem Cells/*transplantation
MH  - Neuroprotective Agents/*administration & dosage/pharmacology
MH  - Piperazines/*administration & dosage/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Thiazoles/*administration & dosage/pharmacology
PMC - PMC3887965
EDAT- 2013/12/03 06:00
MHDA- 2014/07/26 06:00
PMCR- 2014/12/31
CRDT- 2013/12/03 06:00
PHST- 2013/08/22 00:00 [received]
PHST- 2013/11/04 00:00 [accepted]
PHST- 2013/10/25 00:00 [revised]
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2014/07/26 06:00 [medline]
PHST- 2014/12/31 00:00 [pmc-release]
AID - S1016-8478(23)05186-5 [pii]
AID - molcell-36-6-534-6 [pii]
AID - 10.1007/s10059-013-0235-2 [doi]
PST - ppublish
SO  - Mol Cells. 2013 Dec;36(6):534-41. doi: 10.1007/s10059-013-0235-2. Epub 2013 Nov 
      28.